Amit G Singal Selected Research

Liver Diseases (Liver Disease)

3/2022	The Practice of Retransplantation for Recurrent Alcohol-associated Liver Disease in the United States Is Uncommon With Acceptable Outcomes.
1/2022	Decreasing Trend of Serum α-Fetoprotein Level in Hepatocellular Carcinoma.
12/2021	Risk of Hepatocellular Carcinoma in Patients With Indeterminate (LI-RADS 3) Liver Observations.
11/2021	Real-World Effectiveness of Lenvatinib in Hepatocellular Carcinoma Patients with Nonalcoholic Steatohepatitis.
9/2021	Hepatocellular Carcinoma Screening Process Failures in Patients with Cirrhosis.
10/2020	Thrombocytosis is associated with worse survival in patients with hepatocellular carcinoma.
1/2019	Introduction to the Liver Imaging Reporting and Data System for Hepatocellular Carcinoma.
1/2019	Evaluation of a Multifaceted Intervention to Reduce Health Disparities in Hepatitis C Screening: A Pre-Post Analysis.
1/2019	AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review.
1/2018	Knockdown of Anillin Actin Binding Protein Blocks Cytokinesis in Hepatocytes and Reduces Liver Tumor Development in Mice Without Affecting Regeneration.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Amit G Singal Research Topics

Disease

66	Hepatocellular Carcinoma (Hepatoma) 07/2022 - 02/2012
51	Fibrosis (Cirrhosis) 10/2022 - 05/2010
42	Neoplasms (Cancer) 01/2022 - 05/2010
13	Liver Neoplasms (Liver Cancer) 10/2022 - 05/2014
12	Infections 11/2022 - 03/2011
11	Liver Diseases (Liver Disease) 03/2022 - 08/2017
10	Hepatitis C 05/2022 - 04/2012
9	Non-alcoholic Fatty Liver Disease 07/2022 - 02/2016
5	Chronic Hepatitis C 11/2021 - 11/2017
5	End Stage Liver Disease 11/2020 - 10/2013
4	Liver Cirrhosis (Hepatic Cirrhosis) 01/2022 - 01/2019
4	Neoplasm Metastasis (Metastasis) 10/2020 - 12/2015
3	Hepatitis B 11/2021 - 11/2020
3	Pancreatic Neoplasms (Pancreatic Cancer) 01/2021 - 01/2019
3	Thrombocytopenia (Thrombopenia) 10/2020 - 10/2013
2	Hemorrhage 01/2022 - 10/2015
2	Hepatitis 11/2021 - 01/2019
2	Obesity 11/2021 - 01/2019
2	COVID-19 04/2021 - 01/2021
2	Hyponatremia 11/2020 - 10/2013
2	Carcinogenesis 01/2020 - 01/2018
2	Hepatic Encephalopathy 05/2015 - 11/2014
1	Genetic Risk Score 01/2022
1	Cachexia 01/2022
1	Esophageal and Gastric Varices (Esophageal Varices) 01/2022
1	Hypertension (High Blood Pressure) 01/2022
1	Polyps 01/2022
1	Weight Loss (Weight Reduction) 01/2022
1	Diabetes Mellitus 11/2021
1	Esophagitis 11/2021
1	Jaundice (Icterus) 01/2021
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2021
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 11/2020
1	Critical Illness (Critically Ill) 11/2020
1	Thrombocytosis (Thrombocythemia) 10/2020
1	Polyploidy 01/2020
1	Colorectal Neoplasms (Colorectal Cancer) 12/2019
1	Fatigue 10/2019
1	Anorexia 10/2019

Drug/Important Bio-Agent (IBA)

20	Biomarkers (Surrogate Marker)IBA 07/2022 - 10/2014
17	Antiviral Agents (Antivirals)IBA 05/2022 - 03/2013
16	alpha-Fetoproteins (alpha-Fetoprotein)IBA 01/2022 - 01/2014
10	Fetal Proteins (Fetoprotein)IBA 01/2022 - 04/2013
8	Pharmaceutical PreparationsIBA 01/2022 - 03/2017
7	Sorafenib (BAY 43-9006)FDA Link 11/2021 - 05/2010
5	GlycopeptidesIBA 07/2022 - 01/2020
4	Blood Proteins (Serum Proteins)IBA 01/2022 - 01/2021
3	lenvatinibIBA 07/2022 - 07/2021
3	HaptoglobinsIBA 07/2022 - 01/2020
3	Glycoproteins (Glycoprotein)IBA 01/2022 - 01/2019
2	Aspartate Aminotransferases (Aspartate Transaminase)IBA 11/2022 - 08/2017
2	Peptides (Polypeptides)IBA 01/2022 - 01/2021
2	Aligeron (AS 2)IBA 01/2022 - 02/2016
2	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2022
2	perfluoro- 2,2,2',2'- tetramethyl- 4,4'- bis(1,3- dioxolane)IBA 01/2021 - 01/2019
2	RNA (Ribonucleic Acid)IBA 01/2021 - 01/2020
2	ElectrolytesIBA 11/2020 - 11/2014
2	Carbon Tetrachloride (Tetrachloromethane)IBA 01/2020 - 01/2018
2	Diethylnitrosamine (N-Nitrosodiethylamine)IBA 01/2020 - 01/2018
2	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 12/2019 - 01/2019
2	Opioid Analgesics (Opioids)IBA 01/2019 - 03/2016
2	Alanine Transaminase (SGPT)IBA 01/2017 - 10/2013
1	AntigensIBA 07/2022
1	CA-19-9 Antigen (CA 19-9 Antigen)IBA 07/2022
1	atezolizumabIBA 01/2022
1	gadolinium ethoxybenzyl DTPA FDA Link 01/2022
1	cenicrivirocIBA 01/2022
1	Bevacizumab (Avastin)FDA Link 01/2022
1	RamucirumabIBA 01/2022
1	Ceruloplasmin (Ferroxidase)IBA 01/2022
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2022
1	Coloring Agents (Dyes)IBA 11/2021
1	LipidsIBA 10/2021
1	Immunoglobulin M (IgM)IBA 04/2021
1	VaccinesIBA 04/2021
1	Immunoglobulin G (IgG)IBA 04/2021
1	ChloridesIBA 11/2020
1	Biological FactorsIBA 01/2020
1	Doxycycline (Periostat)FDA LinkGeneric 01/2020
1	insulin receptor-related receptor (IRR)IBA 01/2020
1	Biological ProductsIBA 01/2020
1	Immunologic Factors (Immunomodulators)IBA 10/2019
1	Membrane LipidsIBA 10/2019

Therapy/Procedure

40	Therapeutics 10/2022 - 05/2010
21	Liver Transplantation 03/2022 - 05/2010
9	Transplantation 07/2021 - 05/2010
4	Treatment Delay 01/2022 - 09/2013
4	Radiofrequency Ablation 11/2020 - 05/2010
3	Continuity of Patient Care 01/2022 - 10/2014
2	Chemoprevention 01/2022 - 01/2019
2	Surgical Instruments (Clip) 01/2022 - 11/2018
2	Time-to-Treatment 10/2019 - 01/2016
1	Contraindications 01/2022
1	Bariatric Surgery 01/2022
1	Precision Medicine 01/2022
1	Ambulatory Care (Outpatient Care) 09/2021
1	Length of Stay 01/2021
1	Highly Active Antiretroviral Therapy (HAART) 01/2020
1	Palliative Care (Palliative Therapy) 01/2020
1	Secondary Prevention 12/2019